Priority Aviation Inc (PJET): I get into stocks like these before thos...

I get into stocks like these before those

MIKEY501 · 2018-08-20T14:06:18.0770000Z

I get into stocks like these before those kind of events happen. Thats how you get the big wins and Mikey enjoys big wins. PJET Is getting ready for a bigly move. $PJET

Play Episode

6min

Proactive - Interviews for investors

Switch Metals eyes fast-track tantalum output in Côte d'Ivoire as it lists on AIM

Switch Metals Plc (AIM:SWT) CEO Karl Akueson talked with Proactive's Stephen Gunnion about the company’s listing on London’s AIM market and its focus on developing tantalum projects in Côte d'Ivoire. Akueson explained that Switch Metals, a private company he founded, was acquired through a reverse takeover by Oneiro Energy. The company's flagship Issia project hosts tantalum mineralisation, including occurrences of coltan at surface. According to Akueson, this provides an opportunity for near-term production from shallow deposits, with the company aiming to reach output within the next two years. He described tantalum as “a very strategic technology metal… in our mobile phones, laptops, plasma TV, everything we use daily,” highlighting its importance and rarity. Akueson emphasised that 60% of the global supply currently comes from the DRC and Rwanda, and Switch Metals aims to become a significant alternative source. Discussing the decision to list in the UK, Akueson pointed to his personal background and the UK’s long-standing understanding of African production. The £2 million fundraise will support resource definition work at Issia, with plans to quickly define a resource and develop economic parameters to demonstrate value. “Tantalum is probably one of the most critical [metals], and a metal that is unique,” Akueson noted. For more interviews and updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and enable notifications for future content. #Tantalum #SwitchMetals #CotedIvoireMining #CriticalMinerals #AIMListing #JuniorMining #ResourceDefinition #Coltan #TechMetals #ProactiveInvestors

Proactive - Interviews for investors

Race Oncology launches Phase I RC220 trial in Australia

Race Oncology CEO and MD Daniel Tillett talked with Proactive about the opening of patient enrollment at the first Australian clinical site for the RC220 Phase I solid tumour trial. Tillett confirmed that the trial is now underway, with additional sites expected to follow soon. The focus of this early-stage study is to determine a safe and effective combination dose of RC220 with the chemotherapy drug doxorubicin. According to Tillett, “our drug has the advantage… not only does it improve the anti-cancer treatment, but it protects the heart, at least in animals and cells to date.” He noted the choice of Southside Cancer Centre as the initial site, citing the faster startup process compared to public hospitals. Other sites, including Gosford and Wyong, have also received ethics approval and are expected to join the trial following regulatory clearance. Tillett discussed the use of a Bayesian trial design, which allows quicker progression and minimises patient exposure to suboptimal doses. While this approach can introduce uncertainty in timelines, it is expected to be more beneficial overall for patients and the company. Early preclinical data has shown that RC220 can reduce doxorubicin-related toxicity while enhancing cancer treatment outcomes, a combination Tillett described as unique among current therapies. Beyond the trial, Race Oncology is conducting separate preclinical studies to identify the most effective drug combinations using RC220. Tillett noted that more updates on this work are expected in the coming months. Watch the full video to hear more from Daniel Tillett and stay informed on Race Oncology’s developments. ➡️ For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and hit the notification bell for future updates. #RaceOncology #RC220 #CancerResearch #ClinicalTrials #OncologyUpdates #Doxorubicin #CardioProtection #BayesianDesign #CancerTreatment #BiotechNews #ProactiveInve

Proactive - Interviews for investors

Krakatoa’s antimony-gold find signals major upside

Krakatoa Resources Ltd chairman Colin Locke talked with Proactive about the company’s newly secured Zopkhito Project in Georgia, which he described as a major opportunity for investors. The project contains a JORC resource of 225,000 tonnes of high-grade antimony at 11% for 26,000 tonnes of metal, translating to a back-of-the-envelope valuation of approximately $1.30 billion based on current prices. Additionally, the project includes 7.1 million tonnes grading 3.7g/t gold for 815,000 ounces, estimated to be worth around $2.50 billion. Locke said, “This is touted to be the sixth biggest antimony project in the world.” The mineralisation is close to surface, and the company believes the resource has strong potential for expansion. He also highlighted the project’s additional gold content as another value driver. He attributed the company’s success in securing the project to its CEO and chief technical officer, Mark Major, whose experience in high-altitude exploration was a key factor for the local vendors. The project’s location in Georgia was described as highly investor-friendly, with a 15% corporate tax rate, no native title or land access complications, and strong support for foreign investment. Locke confirmed that a maiden drilling program is scheduled to begin shortly, with Major heading to Georgia next week to prepare. He emphasised the company’s past success with international projects and reassured investors of the team’s experience. In closing, he noted the company's current market capitalisation of just AUD 5 million, suggesting significant upside. 👉 For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and turn on notifications for future updates. #ProactiveInvestors #KrakatoaResources #ASX #gold #antimony

Proactive - Interviews for investors

Allergy Therapeutics turns the corner, targets market launches

Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) chief executive Manuel Llobet and chief financial officer Shaun Furlong talked with Proactive's Stephen Gunnion about the company’s financial turnaround and ongoing progress across key clinical programs. Allergy Therapeutics reported a return to operating profit before R&D, exceptional and fundraising costs, supported by topline growth and strict cost control. Llobet highlighted that the company saw a 4% constant currency growth in euro-denominated sales—double that of the previous period—driven by improved supply chains and the strong performance of new and registered products. “The top line is good in terms of quantity and quality,” he said. Furlong added that these results, along with the recent financial restructuring, demonstrate a clear path to sustainable health. The company’s cash position rose to £21.7 million at the end of December from £12.9 million in June, aided by external funding and shareholder support. On the clinical side, Llobet described the Grass MATA MPL program as a potential “game changer”, with a Marketing Authorisation Application submitted in Germany. He also noted the progress of the Polyvac Peanut program, which aims to offer a short-course treatment capable of disease modification, differentiating it from current therapies. The company remains focused on progressing these pipeline assets while maintaining financial discipline. For more exclusive interviews, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe, and turn on notifications to stay updated. #AllergyTherapeutics #BiotechNews #Immunotherapy #GrassMATA #PeanutAllergy #VaccineDevelopment #R&D #Pharmaceuticals #FinancialResults #InvestorUpdates #ProactiveInvestors

Followers	1270
Posts	83691
Boards Moderated	0
Alias Born	07/30/2010

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

PJET Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free